Company intelligence / Profile preview

ML Bio Solutions

Charlotte, North Carolina, United Statesorpha.net ↗

Ownership: Private
Employees: ~7
Development stage: Phase 2

Overview

ML Bio Solutions is developing BBP-418 (Ribitol), an oral disease-modifying investigational treatment for LGMD2I. The drug was granted Orphan Drug Designation for LGMD2i by the FDA in 2019 and for LGMD by the EMA in 2020. The company has completed dosing in Phase 2 trials and has advanced to Phase 3 as of May 2023.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

BBP-418

Phase 2

Indications: Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

Partnerships

GRASP-LGMD consortium based at Virginia Commonwealth University

Beyond the preview

Go deeper on ML Bio Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ML Bio Solutions.

Explore the full profile